MC4R and Genetic obesity: Although direct CNS administration of leptin or MC4R agonists may not be feasible for clinical studies or therapy for MI in humans, new MC4R agonists, such as setmelanotide, cross the blood brain barrier and can be administered peripherally and are already approved by the FDA to treat rare forms of genetic obesity.